Medindia

X

Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results

Wednesday, September 5, 2007 General News J E 4
Advertisement
TUSTIN, Calif., Sept. 4 PeregrinePharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceuticalcompany developing monoclonal antibodies for the treatment of cancer andhepatitis C virus (HCV) infection, today announced that it will release itsfirst quarter FY 2008 financial results ended July 31, 2007 on September 10,2007, and will host a conference call and webcast to discuss the results at11:30 a.m. EDT on the same day.

Participating members of Peregrine senior management will includepresident and chief executive officer Steven W. King and chief financialofficer Paul J. Lytle. Management will discuss financial results for thequarter and review recent operating highlights. A question-and-answer sessionwill follow management's discussion. All interested parties are encouraged tolisten to the live or archived conference call or the live or archivedwebcast.

The conference call and webcast will begin at 11:30 a.m. EDT/8:30 a.m.PDT.

To listen to a live broadcast of the call over the Internet or to reviewthe archived webcast, please visit: http://www.peregrineinc.com. The webcastwill be archived on Peregrine's website for 30 days.

To listen to the call via telephone, please call the following numberapproximately 10 minutes prior to the scheduled time of the conference call:1-800-860-2442 and request to join the Peregrine Pharmaceuticals conferencecall. A telephonic replay of the conference call will be available one hourafter the conclusion of the call through September 17, 2007 by calling(877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection in theU.S. and India with its lead product candidates bavituximab and Cotara(R).Peregrine also has in-house manufacturing capabilities through its whollyowned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), whichprovides development and bio-manufacturing services for both Peregrine andoutside customers. Additional information about Peregrine can be found athttp://www.peregrineinc.com.Contacts: GendeLLindheim BioCom Partners Investors Media info@peregrineinc.com Barbara Lindheim (800) 987-8256 (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Study Demonstrates Martek's Algal DHA Oil Improves...
S
New Poll Shows Public Distrusts Flawed Healthcare ...